Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary.
Over the past few decades, we have gained a better understanding of the risk factors associated with the recurrence of endometrial cancer. Adjuvant postoperative radiotherapy in an intermediate-risk group of endometrial cancer patients resulted in improvement in local control, but survival was not improved significantly. Postoperative management of uterine sarcomas remains investigational. The management of ovarian cancer has notably advanced during the 1990s. Platinum- and paclitaxel-based combination chemotherapy set a new standard of care for patients with advanced ovarian cancer. During the late 1990s, a trend emerged favoring the use of carboplatin over cisplatin for first-line management of advanced ovarian cancer because of its more favorable safety profile. Adjuvant therapy for early-stage high-risk ovarian cancer continues to be actively investigated.
Kim
Robert Y
RY
Department of Radiation Oncology, University of Alabama, Birmingham Comprehensive Cancer Center, Birmingham, Alabama, USA.
Omura
George A
GA
Alvarez
Ronald D
RD
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin